129318-43-0 Usage
Overview
Alendronate sodium is the world's most widely used anti-osteoporosis drugs, listed in the United States in 1993. It can significantly increase bone mineral density, reduce fracture risk, and it is the first-line treatment of osteoporosis drugs. Alendronate sodium is a resorption inhibitor of aminodiphosphonate bone, and has a strong affinity with bone hydroxyapatite. It can enter the bone matrix hydroxyapatite crystals. When the osteoclast dissolved crystals, the drug was released, causing the inhibition of osteoclast activity, and playing anti-bone resorption activity indirectly through the inhibition of bone resorption of osteoblasts.
It possesses the characteristics of the activity of anti-bone resorption and with no bone mineralization. Clinically used for the treatment of postmenopausal women with osteoporosis, to prevent hip and spine fractures.
Synthesis of Alendronate
It uses gamma-aminobutyric acid (GABA), phosphorous acid, phosphorus trichloride as the raw material and uses the diphenyl ether as the solvent to prepare the alendronic acid, and then alkalesizes to obtain its monosodium salt. The synthesis is shown below:
Image 1: Synthesis of Alendronate sodium
Side effects
After medication tolerance well, a small number of patients can be seen gastrointestinal reactions, such as nausea, abdominal distension, abdominal pain, occasional headache, skeletal muscle pain, rare rash and erythema.
The overview of Alendronate sodium, synthesis, adverse reactions, precautions, etc. is edited by lookchem's Li Jie. (2016-01-22)
Taboo
1.Esophageal motility disorders, such as the disability of esophageal delay and the esophageal stricture are disabled.
2.Severe renal insufficiency is disabled.
3.Osteomalacia is disabled.
4.Allergies with the goods and other bisphosphonates, hypokalemia are disabled.
5.Pregnant, lactating women and children are disabled.
Note
1. At least 30 minutes before breakfast with 200ml warm water delivery; medication at least 30 minutes before eating.
2. Taking with orange juice and coffee at the same time will significantly affect the absorption of the product.
3. In taking this product before and after 30 minutes, drinking milk, dairy products and drinks with more calcium are not allowed. Immediately lying in bed after taking medicine may cause esophageal irritation or ulcerative esophagitis.
4. Gastrointestinal disorders, gastritis, esophageal discomfort, duodenitis, ulcer patients should use this drug with caution.
5, Mild to moderate renal dysfunction in patients should use this drug with caution.
6. Before starting to use this product treatment, calcium metabolism and mineral metabolism disorders, vitamin D deficiency and hypocalcemia must be corrected. Calcium supplements, antacids and some oral agents are likely to hinder the absorption of the product. Therefore, after taking this product, the time should be delayed at least half an hour and then taking other drugs.
7. If the food intake is not enough, all patients with osteoporosis should be added calcium and vitamin D.
Drug interactions
1. Antacids and cathartic agents will often affect the absorption of the drug for containing calcium or other metal ions such as magnesium, iron and so on.
2. Inducing hypocalcemia when in combination with aminoglycosides.
Description
Alendronate sodium is the fourth bisphosphonate to reach the market for the treatment
of postmenopausal osteoporosis. Bisphosphonates are potent inhibitors of bone resorption.
They reduce pain and complications due to bone metastases, are effective in Paget's disease
and in increasing bone mineral density. These agents bind tightly to hydroxyapatite crystals
and are retained on bone resorption surfaces. Local release of the bisphosphonates occurs
by acidification during the process of the bone resorption to impair the osteoclasts' ability to
resorb bone. Alendronate is more potent than other bisphosphonates such as clodronate,
pamidronate, and etidronate and is reported to have no deleterious effects on bone. It has
also been shown to reduce hypercalcemia in cancer patients.
Originator
Istituto Gentili (Italy)
Brand name
Alendros
Pharmacokinetics
The second-generation agent alendronate sodium was the first bisphosphonate agent approved by the U.S.
FDA for the prevention and treatment of osteoporosis and Paget's disease of the bone and is 1,000-fold
more potent than etidronate. This derivative, when dosed continuously (5–10 mg/day for osteoporosis and 40
mg/day for Paget's disease) and given with oral calcium supplements (500 mg/day), produced well-mineralized
bone and significantly improved BMD (7% in the spine and 4% in the hip) within 18 months. In addition, the
vertebral fracture rate was shown to decrease by 47%. A side effect associated with alendronate, chemical
esophagitis, has been attributed to inadequate intake of water and lying down after taking the
medication. Specific patient instructions were developed to limit the incidence of upper gastrointestinal
problems and include: 1) taking the medication with 6 to 8 ounces of water on arising in the morning, 2)remaining in an upright position for at least 30 minutes after taking the medication, and 3) delaying drinking
other liquids/eating for at least 30 minutes, if not 1 to 2 hours, to allow maximal absorption of the agent. To
enhance absorption, calcium supplements and any aluminum- or magnesium-containing antacids should be
dosed separately from the agents in this class.
Clinical Use
The second-generation agent alendronate sodium was the first bisphosphonate agent approved by the U.S.
FDA for the prevention and treatment of osteoporosis and Paget's disease of the bone and is 1,000-fold
more potent than etidronate.
Check Digit Verification of cas no
The CAS Registry Mumber 129318-43-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,2,9,3,1 and 8 respectively; the second part has 2 digits, 4 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 129318-43:
(8*1)+(7*2)+(6*9)+(5*3)+(4*1)+(3*8)+(2*4)+(1*3)=130
130 % 10 = 0
So 129318-43-0 is a valid CAS Registry Number.
InChI:InChI=1/C4H13NO7P2.Na/c5-3-1-2-4(6,13(7,8)9)14(10,11)12;/h6H,1-3,5H2,(H2,7,8,9)(H2,10,11,12);/q;+1/p-1